Ohtuvayre (Ensifentrine) for COPD

Overview
Ohtuvayre is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is prescribed to help manage symptoms and improve lung function in people with COPD. Ohtuvayre is also known by its drug name, ensifentrine.

Ohtuvayre is a phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor. It works by relaxing the muscles around the airways in the lungs, reducing inflammation, and helping to keep the airways open, making it easier to breathe.

How do I take it?
Prescribing information states that Ohtuvayre is administered by oral inhalation using a standard jet nebulizer with a mouthpiece. The recommended dosage schedule is twice daily. The drug should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Ohtuvayre include back pain, hypertension (high blood pressure), urinary tract infection, and diarrhea.

Rare but serious side effects may include an increase in psychiatric adverse reactions, including suicidality (risk of suicide). Prescribing information states that, if a person develops paradoxical bronchospasm (unexpected constriction of the airways) while on Ohtuvayre, they should discontinue the treatment and find an alternative therapy.

For more information about this treatment, visit:

Ohtuvayre (Ensifentrine) Inhalation Suspension, for Oral Inhalation Use — U.S. Food and Drug Administration

Ohtuvayre — Drugs.com